Masamitsu Shimazawa Selected Research

adonixanthin

9/2020	Antitumour Effects of Astaxanthin and Adonixanthin on Glioblastoma.
11/2018	Protective effects of the astaxanthin derivative, adonixanthin, on brain hemorrhagic injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masamitsu Shimazawa Research Topics

Disease

29	Ganglion Cysts (Ganglion) 01/2021 - 07/2004
22	Ischemia 01/2022 - 01/2008
19	Brain Ischemia (Cerebral Ischemia) 01/2020 - 01/2005
18	Glaucoma 01/2021 - 01/2004
16	Retinal Diseases 01/2022 - 01/2004
15	Macular Degeneration (Age-Related Maculopathy) 02/2022 - 02/2011
14	Retinal Degeneration 10/2021 - 12/2010
14	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 11/2019 - 01/2005
13	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2022 - 08/2006
13	Retinal Neovascularization 01/2021 - 03/2007
13	Infarction (Infarctions) 01/2020 - 02/2008
12	Choroidal Neovascularization 08/2021 - 09/2014
11	Neoplasms (Cancer) 04/2022 - 11/2009
11	Brain Injuries (Brain Injury) 02/2022 - 08/2008
11	Stroke (Strokes) 01/2020 - 08/2008
10	Retinal Vein Occlusion 01/2022 - 01/2017
9	Papilledema 01/2022 - 06/2017
8	Inflammation (Inflammations) 07/2021 - 08/2013
8	Reperfusion Injury 01/2020 - 10/2009
8	Ischemic Stroke 01/2020 - 01/2011
7	Hypoxia (Hypoxemia) 01/2022 - 08/2006
7	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2020 - 10/2011
6	Glioblastoma (Glioblastoma Multiforme) 04/2022 - 12/2016
6	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2021 - 10/2009
6	Atrophy 01/2021 - 12/2010
6	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 12/2020 - 02/2016
6	Intracranial Hemorrhages (Intracranial Hemorrhage) 11/2020 - 05/2016
6	Retinal Perforations 01/2017 - 08/2006
6	Melanoma (Melanoma, Malignant) 01/2017 - 01/2012
6	Neuroblastoma 01/2015 - 10/2006
5	Macular Edema 01/2022 - 08/2006
5	Hematoma 01/2021 - 01/2017
5	Cerebral Infarction 07/2011 - 06/2007
5	Hyperoxia 05/2011 - 01/2008
4	Ocular Hypertension (Glaucoma, Suspect) 01/2022 - 07/2004
4	Fibrosis (Cirrhosis) 01/2022 - 07/2018
4	Alzheimer Disease (Alzheimer's Disease) 02/2021 - 10/2009
4	Eye Diseases (Eye Disease) 01/2021 - 10/2010
4	Hemorrhage 01/2021 - 02/2015
4	Brain Edema (Cerebral Edema) 01/2020 - 12/2010
4	Blindness (Hysterical Blindness) 01/2018 - 02/2011
4	Pathologic Neovascularization 01/2017 - 08/2009
3	Edema (Dropsy) 01/2022 - 01/2017
3	Mitochondrial Diseases (Mitochondrial Disease) 12/2021 - 01/2020
3	Hemorrhagic Stroke 01/2021 - 01/2017
3	Cerebral Hemorrhage 11/2018 - 01/2017
3	Constipation 10/2012 - 01/2010
3	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2012 - 08/2009
2	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 02/2022 - 01/2022
2	Cognitive Dysfunction 01/2022 - 01/2015

Drug/Important Bio-Agent (IBA)

48	Retinaldehyde (Retinal)IBA 02/2022 - 01/2004
23	Neuroprotective AgentsIBA 01/2022 - 05/2005
20	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 08/2009
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2006
15	Oxygen (Dioxygen)IBA 01/2021 - 01/2007
13	N-Methylaspartate (NMDA)IBA 08/2013 - 08/2005
12	Pharmaceutical PreparationsIBA 01/2021 - 01/2004
10	TunicamycinIBA 01/2015 - 10/2006
9	ProgranulinsIBA 03/2022 - 08/2013
8	AntioxidantsIBA 12/2021 - 01/2010
8	Cilostazol (Pletal)FDA LinkGeneric 01/2017 - 03/2009
7	Free Radical ScavengersIBA 01/2021 - 05/2009
7	EdaravoneIBA 11/2017 - 08/2008
6	astaxanthine (astaxanthin)IBA 09/2020 - 10/2008
6	IgA receptor (protein B)IBA 01/2017 - 01/2012
6	Glycoproteins (Glycoprotein)IBA 01/2017 - 01/2012
5	Indicators and Reagents (Reagents)IBA 04/2015 - 12/2006
5	Glucose (Dextrose)FDA LinkGeneric 09/2014 - 01/2007
5	Propolis (Bee Bread)IBA 10/2012 - 01/2005
4	Collagenases (Collagenase)FDA Link 01/2021 - 01/2017
4	IronIBA 01/2021 - 12/2014
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2009
4	Type 3 Cyclic Nucleotide PhosphodiesterasesIBA 10/2013 - 12/2010
4	LaxativesIBA 10/2012 - 02/2008
4	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 12/2011 - 01/2009
3	4- (4- acetylpiperazin- 1- yl)- 2- (1H- imidazol- 1- yl)anilineIBA 01/2021 - 01/2016
3	Hemoglobins (Hemoglobin)IBA 01/2020 - 10/2013
3	DNA (Deoxyribonucleic Acid)IBA 11/2019 - 01/2012
3	trans-sodium crocetinate (crocetin)IBA 01/2019 - 01/2011
3	Tight Junction ProteinsIBA 01/2019 - 02/2013
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 08/2018 - 08/2013
3	Protein Isoforms (Isoforms)IBA 01/2018 - 12/2012
3	Kallikreins (Kallikrein)IBA 06/2017 - 09/2014
3	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2017 - 03/2009
3	Warfarin (Coumadin)FDA LinkGeneric 01/2017 - 10/2013
3	Sigma-1 ReceptorIBA 03/2015 - 05/2013
3	LigandsIBA 11/2013 - 09/2005
3	Glutamic Acid (Glutamate)FDA Link 06/2012 - 05/2005
3	ZincIBA 12/2009 - 01/2008
2	nafamostatIBA 02/2022 - 01/2022
2	Thrombin FDA Link 01/2022 - 01/2017
2	Scopolamine (Hyoscine)FDA Link 01/2022 - 01/2015
2	Chelating AgentsIBA 01/2021 - 11/2020

Therapy/Procedure

21	Lasers (Laser) 07/2021 - 07/2004
19	Therapeutics 01/2022 - 08/2008
8	Oral Administration 01/2022 - 08/2012
5	Light Coagulation 01/2017 - 07/2004
4	Intravitreal Injections 01/2021 - 08/2005
4	Ligation 11/2016 - 12/2011
2	Intravenous Injections 01/2021 - 06/2017